527 related articles for article (PubMed ID: 29094177)
1. Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis.
Park SH; Keller ET; Shiozawa Y
Calcif Tissue Int; 2018 Feb; 102(2):152-162. PubMed ID: 29094177
[TBL] [Abstract][Full Text] [Related]
2. Biology and clinical management of prostate cancer bone metastasis.
Ye XC; Choueiri M; Tu SM; Lin SH
Front Biosci; 2007 May; 12():3273-86. PubMed ID: 17485298
[TBL] [Abstract][Full Text] [Related]
3. Interaction between Tumor Cell Surface Receptor RAGE and Proteinase 3 Mediates Prostate Cancer Metastasis to Bone.
Kolonin MG; Sergeeva A; Staquicini DI; Smith TL; Tarleton CA; Molldrem JJ; Sidman RL; Marchiò S; Pasqualini R; Arap W
Cancer Res; 2017 Jun; 77(12):3144-3150. PubMed ID: 28428279
[TBL] [Abstract][Full Text] [Related]
4. Rat Prostate Tumor Cells Progress in the Bone Microenvironment to a Highly Aggressive Phenotype.
Bergström SH; Rudolfsson SH; Bergh A
Neoplasia; 2016 Mar; 18(3):152-61. PubMed ID: 26992916
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.
Loberg RD; Logothetis CJ; Keller ET; Pienta KJ
J Clin Oncol; 2005 Nov; 23(32):8232-41. PubMed ID: 16278478
[TBL] [Abstract][Full Text] [Related]
6. Caprylic acid (C8:0) promotes bone metastasis of prostate cancer by dysregulated adipo-osteogenic balance in bone marrow.
Wang C; Wang J; Chen K; Pang H; Li X; Zhu J; Ma Y; Qiu T; Li W; Xie J; Zhang J
Cancer Sci; 2020 Oct; 111(10):3600-3612. PubMed ID: 32770813
[TBL] [Abstract][Full Text] [Related]
7. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.
Russell MR; Jamieson WL; Dolloff NG; Fatatis A
Oncogene; 2009 Jan; 28(3):412-21. PubMed ID: 18850002
[TBL] [Abstract][Full Text] [Related]
8. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
9. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment.
Koeneman KS; Yeung F; Chung LW
Prostate; 1999 Jun; 39(4):246-61. PubMed ID: 10344214
[TBL] [Abstract][Full Text] [Related]
10. Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment.
Arnold RS; Fedewa SA; Goodman M; Osunkoya AO; Kissick HT; Morrissey C; True LD; Petros JA
Bone; 2015 Sep; 78():81-6. PubMed ID: 25952970
[TBL] [Abstract][Full Text] [Related]
11. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
[TBL] [Abstract][Full Text] [Related]
12. The role of tumor microenvironment in prostate cancer bone metastasis.
Morrissey C; Vessella RL
J Cell Biochem; 2007 Jul; 101(4):873-86. PubMed ID: 17387734
[TBL] [Abstract][Full Text] [Related]
13. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer.
Zhang X
Cancer Commun (Lond); 2019 Nov; 39(1):76. PubMed ID: 31753020
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of tumor cells in the bone microenvironment: Mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer.
Futakuchi M; Fukamachi K; Suzui M
Adv Drug Deliv Rev; 2016 Apr; 99(Pt B):206-211. PubMed ID: 26656603
[TBL] [Abstract][Full Text] [Related]
15. Bone metastases in prostate cancer: a targeted approach.
Storey JA; Torti FM
Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
[TBL] [Abstract][Full Text] [Related]
16. [Current diagnosis and the multidisciplinary approach to the treatment of bone metastases in patients with prostate cancer].
Satoh T; Ishiyama H
Nihon Rinsho; 2016 Jan; 74(1):129-36. PubMed ID: 26793893
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of osteoblastic bone metastases from prostate cancer.
Ibrahim T; Flamini E; Mercatali L; Sacanna E; Serra P; Amadori D
Cancer; 2010 Mar; 116(6):1406-18. PubMed ID: 20108337
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of katanin p60 in prostate cancer bone metastasis.
Ye X; Lee YC; Choueiri M; Chu K; Huang CF; Tsai WW; Kobayashi R; Logothetis CJ; Yu-Lee LY; Lin SH
Prostate; 2012 Feb; 72(3):291-300. PubMed ID: 21681775
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression.
Ricci E; Mattei E; Dumontet C; Eaton CL; Hamdy F; van der Pluije G; Cecchini M; Thalmann G; Clezardin P; Colombel M
Prostate; 2013 Dec; 73(16):1738-46. PubMed ID: 24115186
[TBL] [Abstract][Full Text] [Related]
20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
